Pfizer Inc. $PFE Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 22.9% in the second quarter, HoldingsChannel.com reports. The fund owned 126,284 shares of the biopharmaceutical company’s stock after selling 37,464 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Pfizer were worth $3,061,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $27,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the first quarter valued at approximately $28,000. North Capital Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $28,000. WPG Advisers LLC acquired a new position in shares of Pfizer in the first quarter valued at approximately $35,000. Finally, Horizon Financial Services LLC acquired a new position in shares of Pfizer in the first quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $26.27 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a 50 day moving average of $24.76 and a two-hundred day moving average of $24.14. The company has a market cap of $149.36 billion, a P/E ratio of 13.97, a P/E/G ratio of 0.86 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm earned $0.60 earnings per share. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on PFE shares. UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.